

Faculty Disclosures

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, course directors, planners, moderators, faculty, and all others in control of the educational content of the continuing education activity must disclose all financial relationships with ineligible companies that they may have had within the past 24 months. If an individual refuses to disclose financial relationships, they will be disqualified from being a part of the planning and implementation of the activity. Owners and/or employees of an ineligible company with business lines or products relating to the content of the activity will not be permitted to participate in the planning or execution of any accredited program. All listed relevant financial relationships with ineligible companies for individuals in control of content have been mitigated.

Name	Role in Activity	Ineligible Company	Nature of Relevant Financial Relationship
Boland	Faculty, Planning Committee	<ul style="list-style-type: none"> Bristol Myers Squibb, Takeda Pharmaceutical Company, Ltd. 	<ul style="list-style-type: none"> Advisory Board
Collins	Faculty, Planning Committee	<ul style="list-style-type: none"> AbbVie, Inc. Bristol Myers Squibb, Janssen Pharmaceuticals, Takeda Pharmaceutical Company, Ltd. MedscapeTV 	<ul style="list-style-type: none"> Advisor, Speaker Independent Contractor
Coyle	Faculty, Planning Committee	<ul style="list-style-type: none"> AbbVie, Inc. 	<ul style="list-style-type: none"> Speaker's Bureau
DiBaise	Faculty	<ul style="list-style-type: none"> CRC Press, UpToDate Zealand Pharmaceuticals 	<ul style="list-style-type: none"> Consultant Advisor
Dulai	Faculty, Planning Committee	<ul style="list-style-type: none"> AbbVie, Inc., Bristol Myers Squibb, Lilly, Janssen Biosciences, Pfizer, Inc., Takeda Pharmaceutical Company, Ltd. Digbi Health 	<ul style="list-style-type: none"> Consultant Advisor
Ferrari	Faculty, Planning Committee	<ul style="list-style-type: none"> None 	<ul style="list-style-type: none"> N/A
Konijeti	Faculty, Planning Committee	<ul style="list-style-type: none"> Takeda Pharmaceuticals USA, Inc. Pfizer, Inc., ProCiseDx 	<ul style="list-style-type: none"> Speaker Advisor
Matro	Faculty, Planning Committee	<ul style="list-style-type: none"> None 	<ul style="list-style-type: none"> N/A
Moein Jahromi	Peer Reviewer	<ul style="list-style-type: none"> None 	<ul style="list-style-type: none"> N/A
Sandborn	Faculty, Planning Committee	<ul style="list-style-type: none"> AbbVie, Inc., Abivax, Arena Pharmaceuticals, Boehringer Ingelheim, Celgene, Genentech, Gilead Sciences, Glaxo Smith Kline, Janssen, Lilly, Pfizer, Prometheus Biosciences, Seres Therapeutics, Shire, Takeda Pharmaceutical Company, Ltd., Theravance Biopharma AbbVie, Inc., Abivax, Admira, Alfasigma, Alimentiv (previously Robarts Clinical Trials, owned by Alimentiv Health Trust), Alivio Therapeutics, Allakos, Allergan, Amgen, Applied Molecular Transport, Arena Pharmaceuticals, Avexegen Therapeutics, Bausch Health (Salix), BeiGene, Bellatrix Pharmaceuticals, Boehringer Ingelheim, Boston Pharmaceuticals, Bristol Meyer Squibb, Celgene, Celltrion, Cellularity, Conatus, Cosmo Pharmaceuticals, Escalier Biosciences, Ferring, Forbion, Equillum, Genentech/Roche, Gilead Sciences, Glenmark Pharmaceuticals, Gossamer Bio, Immunic (Vital Therapies), Incyte, Index Pharmaceuticals, Intact Therapeutics, Janssen, Kyowa Kirin Pharmaceutical Research, Kyverna Therapeutics, Landos Biopharma, Lilly, Miraca Life Sciences, Nivalis Therapeutics, Novartis, Nutrition Science Partners, Oppilan Pharma, Otsuka, Pandion Therapeutics, Paul Hastings, Pfizer, Progenity, Prometheus Biosciences, Prometheus Laboratories, Protagonists Therapeutics, Provention Bio, Reistone Biopharma, Ritter Pharmaceuticals, Seres Therapeutics, Shanghai Pharma Biotherapeutics, Shire, Shoreline Biosciences, Sienna Biopharmaceuticals, Sigmoid Biotechnologies, Sterna Biologicals, Sublimity Therapeutics, Surrozen, Takeda, Theravance Biopharma, Thetis Pharmaceuticals, Tigenix, Tillotts Pharma, UCB Pharma, Vendata Biosciences, Ventyx Biosciences, Vimalan Biosciences, Vivelix Pharmaceuticals, Vivreon Biosciences, Zealand Pharma Allakos, BeiGene, Gossamer Bio, Oppilan Pharma, Prometheus Biosciences, Prometheus Laboratories, Progenity, Shoreline Biosciences, Ventyx Biosciences, Vimalan Biosciences, Vivreon Biosciences 	<ul style="list-style-type: none"> Research Consultant Stock, Stock Options
Sands	Faculty	<ul style="list-style-type: none"> Arena Pharmaceuticals, AstraZeneca LP, Boehringer-Ingelheim, Bristol Myers-Squibb, Celltrion Healthcare Co. Ltd., Galapagos, Index Pharmaceuticals, Kaleido, Target 	<ul style="list-style-type: none"> Consultant Consultant, Advisory Board Consultant, Speaker

		<p>Pharmasolutions, AbbVie, Alimientiv, Amgen, Bacainn Therapeutics, Boston Pharmaceuticals, Calibr, ClostraBio, Evommune, Glaxo SmithKline, F.Hoffmann-La Roche AG, Innovation Pharmaceuticals, Inotrem, Ironwood Pharmaceuticals, Inc., Kallyope, MiroBio, Otsuka, Q32 Bio, Redhill Biopharma, Lt., Shire, Surrozen, Theravance Biopharma R&D, Inc., USWM Enterprises</p> <ul style="list-style-type: none"> • Abivax, GossamerBio, Janssen, Johnson & Johnson, Lilly, Morphic Therapeutic, Pfizer, Prometheus Bioscience, Vivante Health, Ventyx Biosciences, Genentech, Inc., Immunic AG, Oppilan Pharma, Ltd., OSE Immunotherapeutics, Prometheus Laboratories • Takeda 	
Singh	Faculty, Planning Committee	<ul style="list-style-type: none"> • AbbVie, Inc., Janssen Biosciences • Pfizer, Inc. 	<ul style="list-style-type: none"> • Research Funding • Advisor
Sklow	Faculty	<ul style="list-style-type: none"> • None 	<ul style="list-style-type: none"> • N/A
Worsey	Faculty, Planning Committee	<ul style="list-style-type: none"> • None 	<ul style="list-style-type: none"> • N/A
CME Committee	CE approval, all final decision-making on activities	<ul style="list-style-type: none"> • None 	<ul style="list-style-type: none"> • N/A
Scripps Conference Services & CME	Plan, manage, implement, and reconcile CE activities	<ul style="list-style-type: none"> • None 	<ul style="list-style-type: none"> • N/A

Glossary of Terms

Ineligible Company

An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. For specific examples of ineligible companies visit www.accme.org/standards.

Financial Relationships

Financial relationships include employee, researcher, consultant, advisor, speaker, independent contractor, research funding, royalties or patent beneficiary, executive role, and ownership interest. Individual stocks and stock options should be disclosed.